Resumen de The FDA Approves One New Hyperkalemia Drug, Requires Drug Interaction Study for Another

Diane S. Aschenbrenner

• * Patiromer (Veltassa), an oral suspension that binds potassium in the gastrointestinal tract, has been approved to treat hyperkalemia.

  * Patiromer binds to many medicines, potentially decreasing their effectiveness. Thus nurses should instruct patients to take patiromer at least six hours before or after taking other medications.

  * Because significant interactions between patiromer and sodium polystyrene sulfonate (Kayexalate) are possible, the Food and Drug Administration has required that a drug interaction study be completed by Kayexalate's manufacturer.